DBV Technologies SA (DBV):製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】DBV Technologies SA (DBV) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C3329)・商品コード:DATA904C3329
・発行会社(調査会社):GlobalData
・発行日:2018年8月
・ページ数:57
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
DBV Technologies SA (DBV) is a biopharmaceutical company that develops products for the diagnosis and treatment of food and pediatric allergies. The company develops and markets non-invasive epicutaneous delivery technology and products for healthcare markets. Its viaskin technology platform is an electrostatic patch that provides a suitable, self-administered and non-invasive immunotherapy to patients. DBV’s products include Viaskin Peanut for the treatment of peanut allergies; Viaskin Milk for cow’s protein milk allergies; Viaskin Egg for the treatment of egg allergy and Viaskin Plateform, among others. The company works in collaboration with institutes, universities and pharmaceutical companies. It conducts research in existing and new indications. The company operates in the US and France. DBV is headquartered in Montrouge, France.

DBV Technologies SA (DBV) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
DBV Technologies SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
DBV Technologies SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
DBV Technologies SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
DBV Technologies SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
DBV Technologies SA, Medical Devices Deals, 2012 to YTD 2018 10
DBV Technologies SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
DBV Technologies SA, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
DBV Technologies Enters Into Research Agreement With Icahn School of Medicine at Mount Sinai For Viaskin 12
DBV Technologies Enters into Agreement with BioNet-Asia and University of Geneva 14
DBV Technologies Enters Into Research Agreement With Inserm For Viaskin 15
DBV Technologies Enters Into Research Agreement With Stallergenes 17
DBV Technologies Exercises Option for R&D Agreement with Stallergenes for Birch Allergy Treatment 18
DBV Technologies Enters Into Research Agreement With Mount Sinai Hospital 19
Equity Offering 20
DBV Technologies Raises USD59.2 Million in Public Offering of Shares 20
DBV Technologies Raises USD91 Million in Private Placement of Shares 22
DBV Technologies Completes Public Offering of American Depositary Shares for USD281.5 Million 24
DBV Technologies Raises USD106.5 Million in Public Offering of Shares 26
DBV Technologies Raises USD34 Million in Private Placement of Shares 28
DBV Technologies Raises USD22.8 Million in Private Placement of Shares 30
DBV Technologies Completes IPO for USD53.6 Million 32
Acquisition 34
Stallergenes Acquires 2% Stake in DBV Technologies 34
DBV Technologies SA – Key Competitors 35
DBV Technologies SA – Key Employees 36
DBV Technologies SA – Locations And Subsidiaries 37
Head Office 37
Other Locations & Subsidiaries 37
Recent Developments 38
Financial Announcements 38
Mar 14, 2018: DBV Technologies Reports Full Year 2017 Financial Results 38
Jul 28, 2017: DBV Technologies Reports First Half 2017 Financial Results 39
Mar 15, 2017: DBV Technologies Reports Full Year 2016 Financial Results 40
Corporate Communications 41
Jun 15, 2017: DBV Technologies Announces Appointment of Julie O’Neill to Board of Directors 41
Product News 42
10/12/2017: DBV Technologies Announces Completion of Blinded Period in REALISE Study of Viaskin Peanut 42
06/17/2017: DBV Technologies Highlights Poster Presentations on EPIT at the 2017 EAACI Congress 43
Clinical Trials 44
Nov 20, 2017: DBV Technologies Announces Positive Topline Safety Results from REALISE Phase III Trial of Viaskin Peanut for the Treatment of Peanut-Allergic Patients 44
Nov 14, 2017: DBV Technologies Announces Publication of Positive Data from Phase IIb Trial and Long-Term Study of Viaskin Peanut in the Journal of the American Medical Association 46
Oct 20, 2017: DBV Technologies Announces Topline Results of Phase III Clinical Trial in Peanut-Allergic Patients Four to 11 Years of Age 48
Aug 29, 2017: DBV Technologies Announces Completion of Enrollment in Phase III Extension Study of Viaskin Peanut 50
Aug 02, 2017: DBV Technologies Initiates Phase III Study of Viaskin Peanut in Peanut-Allergic Patients One to Three Years of Age 51
Mar 10, 2017: DBV Technologies Announces Completion of Enrollment of the REALISE Study in Peanut Allergic Children 52
Mar 05, 2017: Data at AAAAI 2017 Show Lasting Response and Favorable Safety Profile of Investigational Agent, Viaskin Peanut, Throughout Three Years of Treatment of Peanut Allergic Children 53
Feb 03, 2017: DBV Technologies Announces Completion of Enrollment of Phase IIA Study of Viaskin Milk for the Treatment of Pediatric Eosinophilic Esophagitis 55
Other Significant Developments 56
Jul 27, 2018: DBV Technologies Reports June 30, 2018 Cash Position 56
Appendix 57
Methodology 57
About GlobalData 57
Contact Us 57
Disclaimer 57

List of Tables
DBV Technologies SA, Pharmaceuticals & Healthcare, Key Facts, 2017 2
DBV Technologies SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
DBV Technologies SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
DBV Technologies SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
DBV Technologies SA, Deals By Therapy Area, 2012 to YTD 2018 9
DBV Technologies SA, Medical Devices Deals, 2012 to YTD 2018 10
DBV Technologies SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
DBV Technologies Enters Into Research Agreement With Icahn School of Medicine at Mount Sinai For Viaskin 12
DBV Technologies Enters into Agreement with BioNet-Asia and University of Geneva 14
DBV Technologies Enters Into Research Agreement With Inserm For Viaskin 15
DBV Technologies Enters Into Research Agreement With Stallergenes 17
DBV Technologies Exercises Option for R&D Agreement with Stallergenes for Birch Allergy Treatment 18
DBV Technologies Enters Into Research Agreement With Mount Sinai Hospital 19
DBV Technologies Raises USD59.2 Million in Public Offering of Shares 20
DBV Technologies Raises USD91 Million in Private Placement of Shares 22
DBV Technologies Completes Public Offering of American Depositary Shares for USD281.5 Million 24
DBV Technologies Raises USD106.5 Million in Public Offering of Shares 26
DBV Technologies Raises USD34 Million in Private Placement of Shares 28
DBV Technologies Raises USD22.8 Million in Private Placement of Shares 30
DBV Technologies Completes IPO for USD53.6 Million 32
Stallergenes Acquires 2% Stake in DBV Technologies 34
DBV Technologies SA, Key Competitors 35
DBV Technologies SA, Key Employees 36
DBV Technologies SA, Other Locations 37
DBV Technologies SA, Subsidiaries 37

List of Figures
DBV Technologies SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
DBV Technologies SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
DBV Technologies SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
DBV Technologies SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
DBV Technologies SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
DBV Technologies SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
DBV Technologies SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
DBV Technologies SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
DBV Technologies SA, Medical Devices Deals, 2012 to YTD 2018 10

★調査レポート[DBV Technologies SA (DBV):製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C3329)販売に関する免責事項を必ずご確認ください。
★調査レポート[DBV Technologies SA (DBV):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆